COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics.

Claire J PeetCharalampia PapadopoulouBella Ruth M SombritoMichael R WoodHelen J Lachmann

Published in: Rheumatology advances in practice (2021)

These data, including the largest published series of patients on anti-IL-1/6 biologics to receive any adenoviral vector or messenger RNA vaccine, show no serious early concerns regarding vaccination and will provide an urgently needed resource to inform decision-making of these patients and their clinicians.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
prognostic factors
peritoneal dialysis
decision making
sars cov
type diabetes
risk factors
patient reported outcomes
metabolic syndrome
insulin resistance
deep learning
artificial intelligence
meta analyses